Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 62 full-time employees. The firm focuses on improving the lives of patients with genetically defined rare diseases. The firm have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The firm is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders.
Website: fulcrumtx.com



Growth: Bad revenue growth rate -50.0%, there is slowdown compared to average historical growth rates 107.7%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -673.3%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -8.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 308.0% higher than minimum and 34.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -28.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FULC
Share price, USD:  (-3.0%)9.22
year average price 5.08  


year start price 3.82 2024-10-06

min close price 2.51 2025-04-04

max close price 9.51 2025-10-02

current price 9.22 2025-10-06
Common stocks: 40 848 199

Dividend Yield:  0.0%
EV / Sales: 23.4x
Margin (EBITDA LTM / Revenue): -673.3%
Fundamental value created in LTM:
Market Cap ($m): 377
Net Debt ($m): -26
EV (Enterprise Value): 351
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-29globenewswire.com

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

2025-07-29globenewswire.com

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

2025-05-29globenewswire.com

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

2025-02-18globenewswire.com

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

2024-11-28zacks.com

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

2024-11-13seekingalpha.com

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

2024-10-14accesswire.com

Fulcrum Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - FULC

2024-10-11accesswire.com

Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud

2024-10-10accesswire.com

Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - FULC

2024-10-09zacks.com

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FULC FULC FULC FULC FULC FULC FULC FULC FULC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-07-31 2024-05-13 2024-02-27 2023-11-07 2023-08-03 2023-05-15 2023-03-09 2022-11-08
acceptedDate 2024-11-13 07:10:23 2024-07-31 07:15:28 2024-05-13 07:15:36 2024-02-27 16:01:55 2023-11-07 07:05:30 2023-08-03 07:11:11 2023-05-15 07:08:37 2023-03-09 07:21:02 2022-11-08 07:43:53
calendarYear 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
revenue 0 80M 0 871 000 759 000 880 000 295 000 685 000 1M
costOfRevenue 0 17M 479 000 508 000 500 000 600 000 0 0 0
grossProfit 0 63M -479 000 363 000 259 000 280 000 295 000 685 000 1M
grossProfitRatio 0 0.784 0 0.417 0.341 0.318 1 1 1
researchAndDevelopmentExpenses 15M 17M 19M 19M 18M 18M 17M 19M 15M
generalAndAdministrativeExpenses 8M 10M 10M 10M 10M 10M 12M 10M 10M
sellingAndMarketingExpenses 0 0 0 -508 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 8M 10M 10M 9M 10M 10M 12M 10M 10M
otherExpenses 2M 0 3M 3M 3M 4M 3M 2M 0
operatingExpenses 25M 28M 29M 28M 28M 28M 28M 29M 25M
costAndExpenses 25M 28M 30M 29M 28M 28M 28M 29M 25M
interestIncome 0 0 0 -7M 0 4M 0 0 0
interestExpense 0 0 0 3M 0 0 -3M -2M -617 000
depreciationAndAmortization 369 000 0 479 000 -39 586 531 000 567 000 566 000 -76 000 2M
ebitda -25M 56M -29M -27M -27M -27M -28M -28M -23M
ebitdaratio 0 0.656 0 -31.555 -35.453 -30.369 -94.712 -40.947 -19.285
operatingIncome -25M 52M -30M -28M -27M -27M -28M -28M -24M
operatingIncomeRatio 0 0.656 0 -32.138 -36.153 -31.014 -94.712 -40.836 -20.587
totalOtherIncomeExpensesNet 3M 3M 3M 3M 3M 4M 3M 2M 617 000
incomeBeforeTax -22M 55M -27M -25M -24M -24M -25M -26M -24M
incomeBeforeTaxRatio 0 0.693 0 -28.423 -31.643 -27.026 -83.997 -38.153 -20.066
incomeTaxExpense 0 0 435 188 3M 0 0 -3M -3M 313 000
netIncome -22M 55M -27M -25M -24M -24M -22M -24M -24M
netIncomeRatio 0 0.693 0 -28.423 -31.643 -27.026 -73.281 -34.496 -20.331
eps -0.35 0.89 -0.43 -0.4 -0.39 -0.38 -0.36 -0.45 -0.52
epsdiluted -0.35 0.87 -0.43 -0.4 -0.39 -0.38 -0.36 -0.45 -0.52
weightedAverageShsOut 62M 62M 62M 62M 62M 62M 60M 52M 46M
weightedAverageShsOutDil 62M 64M 62M 62M 62M 62M 60M 52M 46M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FULC FULC FULC FULC FULC FULC FULC FULC FULC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-07-31 2024-05-13 2024-02-27 2023-11-07 2023-08-03 2023-05-15 2023-03-09 2022-11-08
acceptedDate 2024-11-13 07:10:23 2024-07-31 07:15:28 2024-05-13 07:15:36 2024-02-27 16:01:55 2023-11-07 07:05:30 2023-08-03 07:11:11 2023-05-15 07:08:37 2023-03-09 07:21:02 2022-11-08 07:43:53
calendarYear 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
cashAndCashEquivalents 73M 87M 40M 26M 30M 34M 35M 35M 91M
shortTermInvestments 185M 187M 173M 211M 227M 244M 263M 168M 131M
cashAndShortTermInvestments 257M 274M 213M 236M 257M 278M 298M 203M 222M
netReceivables 4M 4M 1M 2M 2M 2M 1M 1M 1M
inventory 0 0 0 0 -1M -1M -1M -852 000 0
otherCurrentAssets 5M 3M 4M 4M 5M 4M 5M 4M 5M
totalCurrentAssets 267M 280M 218M 242M 262M 283M 303M 208M 228M
propertyPlantEquipmentNet 10M 11M 11M 12M 13M 14M 15M 16M 17M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 1M 1M 1M 1M 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 1M 3M 2M 2M 2M 2M 3M 3M 3M
totalNonCurrentAssets 12M 14M 15M 15M 16M 17M 18M 19M 20M
otherAssets 0 0 1 0 0 0 0 0 0
totalAssets 279M 294M 233M 258M 279M 300M 321M 227M 248M
accountPayables 4M 4M 4M 3M 4M 4M 4M 4M 3M
shortTermDebt 2M 2M 2M 2M 2M 3M 3M 3M 3M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 -2M 0 334 000 513 000 737 000 934 000 1M
otherCurrentLiabilities 8M 7M 7M 9M 8M 8M 7M 10M 8M
totalCurrentLiabilities 15M 13M 11M 14M 14M 15M 14M 17M 15M
longTermDebt 7M 8M 8M 9M 9M 10M 10M 11M 11M
deferredRevenueNonCurrent 0 0 0 197 000 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 -197 000 0 0 0 0 0
otherNonCurrentLiabilities 197 000 197 000 196 999 197 000 197 000 447 000 320 000 197 000 5M
totalNonCurrentLiabilities 7M 8M 8M 9M 9M 10M 10M 11M 12M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 9M 10M 8M 9M 11M 12M 13M 13M 14M
totalLiabilities 22M 20M 19M 23M 23M 25M 25M 28M 26M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 54 000 62 000 62 000 62 000 62 000 62 000 62 000 52 000 52 000
retainedEarnings -503M -481M -537M -510M -485M -461M -437M -412M -386M
accumulatedOtherComprehensiveIncomeLoss 379 000 -366 000 -434 000 -136 000 -886 000 -1M -651 000 -797 000 -921 000
othertotalStockholdersEquity 760M 755M 751M 745M 741M 737M 734M 612M 608M
totalStockholdersEquity 257M 274M 214M 235M 255M 275M 296M 199M 221M
totalEquity 257M 274M 214M 235M 255M 275M 296M 199M 221M
totalLiabilitiesAndStockholdersEquity 279M 294M 233M 258M 279M 300M 321M 227M 248M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 279M 294M 233M 258M 279M 300M 321M 227M 248M
totalInvestments 185M 187M 175M 212M 227M 244M 263M 168M 131M
totalDebt 9M 10M 10M 11M 11M 12M 13M 13M 14M
netDebt -63M -77M -30M -15M -19M -22M -22M -22M -77M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol FULC FULC FULC FULC FULC FULC FULC FULC FULC
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-07-31 2024-05-13 2024-02-27 2023-11-07 2023-08-03 2023-05-15 2023-03-09 2022-11-08
acceptedDate 2024-11-13 07:10:23 2024-07-31 07:15:28 2024-05-13 07:15:36 2024-02-27 16:01:55 2023-11-07 07:05:30 2023-08-03 07:11:11 2023-05-15 07:08:37 2023-03-09 07:21:02 2022-11-08 07:43:53
calendarYear 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
netIncome -22M 55M -27M -25M -24M -24M -25M -26M -24M
depreciationAndAmortization 345 000 376 000 479 000 508 000 531 000 567 000 566 000 591 000 611 000
deferredIncomeTax 0 0 0 -5M 0 0 0 0 0
stockBasedCompensation 4M 4M 4M 3M 4M 3M 4M 3M 3M
changeInWorkingCapital 2M -96 000 -2M -1M -2M 780 000 -3M 3M -8M
accountsReceivables -1M 0 537 000 43 000 76 000 -557 000 130 000 13 000 344 000
inventory 0 0 0 1 -76 000 557 000 0 0 0
accountsPayables 297 000 -293 000 1M -817 000 -287 000 163 000 88 000 903 000 -3M
otherWorkingCapital 3M 197 000 -3M -257 000 -1M 617 000 -3M 2M -6M
otherNonCashItems -3M -1M 2M 4M -2M -2M -1M -601 000 112 000
netCashProvidedByOperatingActivities -19M 59M -25M -23M -23M -21M -24M -20M -28M
investmentsInPropertyPlantAndEquipment -19 000 0 -28 000 -77 000 -65 000 -195 000 -171 000 -116 000 -283 000
acquisitionsNet 0 0 0 -18M 55M 74M 0 0 0
purchasesOfInvestments -38M -63M -56M -25M -26M -17M -127M -83M -53M
salesMaturitiesOfInvestments 43M 51M 94M 44M 45M 37M 33M 47M 51M
otherInvestingActivites 0 0 38M 18M -55M -74M 0 0 0
netCashUsedForInvestingActivites 4M -13M 38M 18M 19M 20M -94M -36M -2M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 635 000 377 000 2M 287 000 0 142 000 117M -49 000 81M
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 635 000 377 000 2M 287 000 118M 0 348 000 267 000 93 000
netCashUsedProvidedByFinancingActivities 635 000 377 000 2M 287 000 118M 142 000 118M 218 000 81M
effectOfForexChangesOnCash 0 0 0 119M -119M -364 000 0 0 0
netChangeInCash -13M 47M 14M -5M -4M -768 000 -364 000 -56M 51M
cashAtEndOfPeriod 74M 87M 40M 26M 31M 35M 36M 36M 92M
cashAtBeginningOfPeriod 87M 40M 26M 30M 35M 36M 36M 92M 41M
operatingCashFlow -19M 59M -25M -23M -23M -21M -24M -20M -28M
capitalExpenditure -19 000 0 -28 000 -77 000 -65 000 -195 000 -171 000 -116 000 -283 000
freeCashFlow -19M 59M -25M -23M -23M -21M -24M -20M -28M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-13 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-13 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-05 ET (fiscal 2023 q2)
2023 q1
2023-05-15 ET (fiscal 2023 q1)
2022 q4
2023-03-10 ET (fiscal 2022 q4)
2022 q3
2022-11-12 ET (fiscal 2022 q3)
2022 q2
2022-08-11 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-13 12:00 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024
2024-11-12 21:05 ET
Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference
2024-11-06 13:00 ET
Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET
2024-10-11 20:30 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-09-12 10:55 ET
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
2024-08-27 20:05 ET
Fulcrum Therapeutics to Participate in Upcoming September Conferences
2024-08-19 11:00 ET
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
2024-07-31 11:00 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
2024-07-24 12:00 ET
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
2024-06-12 12:00 ET
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
2024-06-06 12:00 ET
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
2024-05-13 11:00 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
2024-05-13 10:00 ET
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
2024-05-09 12:00 ET
Fulcrum Therapeutics to Participate in Upcoming May Conferences
2024-05-08 12:00 ET
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
2024-05-06 12:00 ET
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
2024-03-28 20:05 ET
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
2024-03-22 20:30 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 11:00 ET
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
2024-03-08 21:30 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-05 13:00 ET
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
2024-02-27 12:00 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
2024-02-20 21:01 ET
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
2024-02-06 13:00 ET
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2023-12-07 21:30 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-10 21:30 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-09 13:00 ET
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
2023-11-07 12:00 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
2023-10-31 12:50 ET
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
2023-09-22 12:00 ET
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
2023-09-15 20:30 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-07 12:00 ET
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
2023-08-22 11:00 ET
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
2023-08-11 20:53 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 11:01 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
2023-08-03 10:55 ET
Fulcrum Therapeutics Appoints Chief Financial Officer
2023-07-27 11:00 ET
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
2023-07-10 11:00 ET
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
2023-07-07 21:30 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-20 11:00 ET
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
2023-06-09 20:54 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-15 11:05 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
2023-05-15 11:00 ET
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
2023-05-08 20:05 ET
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
2023-05-05 22:06 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-04-07 21:00 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-04-05 12:00 ET
Fulcrum Therapeutics Announces CFO Resignation
2023-03-10 22:00 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-09 12:00 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
2023-03-06 21:05 ET
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
2023-02-24 13:00 ET
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
2023-02-10 22:27 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-08 22:00 ET
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
2023-01-18 04:15 ET
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2023-01-17 21:01 ET
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
2023-01-13 22:00 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-04 12:02 ET
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
2023-01-04 12:01 ET
Fulcrum Therapeutics Announces CEO Transition
2022-12-05 22:20 ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-01 21:01 ET
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
2022-11-11 23:33 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-08 12:17 ET
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
2022-11-07 22:00 ET
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
2022-11-02 11:05 ET
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
2022-11-01 21:29 ET
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
2022-10-12 11:30 ET
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
2022-10-07 21:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-09 21:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-06 20:01 ET
Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences
2022-08-16 11:05 ET
Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit
2022-08-16 01:28 ET
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
2022-08-15 20:08 ET
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
2022-08-11 11:00 ET
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
2022-08-04 12:07 ET
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8:00 a.m. ET
2022-08-02 12:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-07-15 12:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-07-11 21:00 ET
Fulcrum Therapeutics Announces Departure of Chief Medical Officer
2022-07-05 11:00 ET
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
2022-06-10 20:02 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-10 11:02 ET
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
2022-05-12 21:08 ET
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
2022-05-09 11:00 ET
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
2022-05-06 12:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-05 12:00 ET
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
2022-05-02 12:00 ET
Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8:00 a.m. ET
2022-04-08 12:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-01 12:30 ET
Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting
2022-03-17 12:00 ET
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
2022-03-14 12:00 ET
Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference
2022-03-11 13:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-03 12:01 ET
Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
2022-03-03 12:00 ET
Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
2022-02-24 13:00 ET
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET
2022-02-11 13:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-02-10 13:00 ET
Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference
2022-01-10 12:00 ET
Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
2022-01-07 13:00 ET
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-06 13:00 ET
Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
2022-01-04 13:00 ET
Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer
2021-12-06 12:00 ET
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
2021-11-17 13:00 ET
Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors
2021-11-04 11:00 ET
Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results
2021-11-03 11:00 ET
Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
2021-10-28 11:00 ET
Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET
2021-10-01 11:00 ET
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021-09-20 11:00 ET
Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society
2021-09-10 11:00 ET
Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2021-09-08 11:00 ET
Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer
2021-09-02 11:00 ET
Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences
2021-08-16 20:01 ET
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2021-08-12 02:09 ET
Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock
2021-08-10 20:24 ET
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
2021-08-10 11:01 ET
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
2021-08-10 11:00 ET
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
2021-08-04 11:00 ET
Fulcrum Therapeutics to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Tuesday, August 10, 2021 at 8:00 a.m. ET
2021-06-24 11:00 ET
Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
2021-06-21 11:00 ET
Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress (IRC)
2021-05-12 11:00 ET
Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
2021-05-07 11:00 ET
Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
2021-05-06 11:01 ET
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
2021-05-06 11:00 ET
Fulcrum Therapeutics Appoints Christopher Morabito, M.D. as Chief Medical Officer
2021-04-29 11:00 ET
Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET
2021-04-09 17:15 ET
Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference
2021-03-24 13:29 ET
Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
2021-03-18 15:30 ET
Fulcrum Therapeutics Presents Data for Potential FSHD Biomarker and Clinical Outcome Assessments at 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
2021-03-04 12:01 ET
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
2021-03-04 12:00 ET
Fulcrum Therapeutics Announces CEO Transition
2021-02-26 12:00 ET
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET
2021-02-26 12:00 ET
Fulcrum Therapeutics Recognizes Rare Disease Day 2021
2021-02-19 12:00 ET
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
2021-01-22 21:00 ET
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2021-01-20 03:34 ET
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
2021-01-19 21:01 ET
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
2021-01-19 21:00 ET
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
2021-01-06 12:00 ET
Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference
2020-12-09 12:00 ET
Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease
2020-12-05 15:00 ET
Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
2020-11-13 12:30 ET
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
2020-11-10 12:00 ET
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
2020-11-04 21:01 ET
Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
2020-11-03 12:00 ET
Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8:00 a.m. ET
2020-10-05 11:00 ET
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
2020-10-01 11:00 ET
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
2020-09-25 18:15 ET
Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting
2020-09-08 11:00 ET
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
2020-08-11 11:01 ET
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
2020-08-11 11:00 ET
Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
2020-08-06 11:00 ET
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
2020-08-05 11:00 ET
Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8:00 a.m. ET
2020-07-21 11:30 ET
MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies
2020-06-24 11:00 ET
Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients
2020-06-10 11:01 ET
Fulcrum Therapeutics Completes $68.5 Million Private Placement
2020-06-10 11:00 ET
Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19
2020-05-21 11:00 ET
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
2020-05-13 11:00 ET
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
2020-05-11 11:00 ET
Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference
2020-05-07 11:00 ET
Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET
2020-04-13 11:00 ET
Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease
2020-04-02 11:00 ET
Fulcrum Therapeutics Provides Business Update on Impact of COVID-19
2020-03-24 18:20 ET
Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
2020-03-05 12:00 ET
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results
2020-02-28 12:00 ET
Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020
2020-02-26 12:00 ET
Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
2020-02-25 13:00 ET
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Thursday, March 5, 2020 at 8:00 a.m. ET
2020-02-20 13:01 ET
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
2020-01-29 13:01 ET
Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio
2020-01-06 12:00 ET
Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors
2019-12-30 12:30 ET
Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement
2019-12-02 15:37 ET
Fulcrum Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
2019-11-14 12:00 ET
Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
2019-11-13 13:01 ET
Fulcrum Therapeutics to Present at the Stifel 2019 Healthcare Conference
2019-11-06 13:01 ET
Fulcrum Therapeutics to Report Third Quarter 2019 Financial Results on Thursday, November 14, 2019
2019-10-31 12:00 ET
Fulcrum Therapeutics to Host Key Opinion Leader Breakfast Symposium on Facioscapulohumeral Dystrophy (FSHD), on November 7, 2019
2019-10-04 08:30 ET
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
2019-10-01 11:00 ET
Fulcrum Therapeutics Announces Multiple Presentations of Losmapimod Data at World Muscle Society Meeting
ET
Fulcrum Therapeutics to Participate in Upcoming December Conferences
ET
Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ET
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET
ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
ET
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ET
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
ET
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
ET
Fulcrum Therapeutics to Participate in Upcoming May Conferences
ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ET
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
ET
Fulcrum Therapeutics to Present at Upcoming Medical Meetings
ET
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ET
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
ET
Fulcrum Therapeutics to Present at Upcoming Investor Meetings

SEC forms

Show financial reports only

SEC form 8
2025-08-28 14:41 ET
Fulcrum Therapeutics published news for 2025 q2
SEC form 8
2025-08-28 14:41 ET
Fulcrum Therapeutics published news for 2025 q2
SEC form 10
2025-07-29 12:39 ET
Fulcrum Therapeutics reported for 2025 q2
SEC form 8
2025-07-29 12:34 ET
Fulcrum Therapeutics published news for 2025 q2
SEC form 8
2025-07-29 12:34 ET
Fulcrum Therapeutics published news for 2025 q2
SEC form 8
2025-07-29 12:34 ET
Fulcrum Therapeutics published news for 2025 q2
SEC form 10
2025-05-01 11:10 ET
Fulcrum Therapeutics reported for 2025 q1
SEC form 8
2025-05-01 11:05 ET
Fulcrum Therapeutics published news for 2025 q1
SEC form 8
2025-05-01 11:05 ET
Fulcrum Therapeutics published news for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Fulcrum Therapeutics reported for 2025 q1
SEC form 10
2025-02-25 12:10 ET
Fulcrum Therapeutics reported for 2024 q4
SEC form 10
2025-02-25 00:00 ET
Fulcrum Therapeutics reported for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Fulcrum Therapeutics published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Fulcrum Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Fulcrum Therapeutics published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Fulcrum Therapeutics published news for 2024 q4
SEC form 10
2024-11-13 07:10 ET
Fulcrum Therapeutics reported for 2024 q3
SEC form 8
2024-11-13 07:05 ET
Fulcrum Therapeutics published news for 2024 q3
SEC form 8
2024-11-13 07:05 ET
Fulcrum Therapeutics published news for 2024 q3
SEC form 10
2024-11-13 00:00 ET
Fulcrum Therapeutics reported for 2024 q3
SEC form 10
2024-07-31 07:15 ET
Fulcrum Therapeutics reported for 2024 q2
SEC form 8
2024-07-31 07:10 ET
Fulcrum Therapeutics published news for 2024 q2
SEC form 8
2024-07-31 07:10 ET
Fulcrum Therapeutics published news for 2024 q2
SEC form 10
2024-07-31 00:00 ET
Fulcrum Therapeutics reported for 2024 q2
SEC form 10
2024-05-13 07:15 ET
Fulcrum Therapeutics reported for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Fulcrum Therapeutics reported for 2024 q1
SEC form 10
2024-02-27 16:01 ET
Fulcrum Therapeutics reported for 2023 q4
SEC form 8
2024-02-27 07:01 ET
Fulcrum Therapeutics published news for 2023 q4
SEC form 8
2024-02-27 07:01 ET
Fulcrum Therapeutics published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Fulcrum Therapeutics reported for 2023 q4
SEC form 10
2023-11-07 07:05 ET
Fulcrum Therapeutics reported for 2023 q3
SEC form 8
2023-11-07 07:02 ET
Fulcrum Therapeutics published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Fulcrum Therapeutics reported for 2023 q3
SEC form 10
2023-08-03 07:11 ET
Fulcrum Therapeutics reported for 2023 q2
SEC form 6
2023-08-03 07:05 ET
Fulcrum Therapeutics reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Fulcrum Therapeutics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Fulcrum Therapeutics reported for 2023 q2
SEC form 6
2023-07-10 17:06 ET
Fulcrum Therapeutics published news for 2023 q2
SEC form 6
2023-07-03 16:16 ET
Fulcrum Therapeutics published news for 2023 q2
SEC form 6
2023-06-23 17:40 ET
Fulcrum Therapeutics published news for 2023 q1
SEC form 6
2023-06-23 17:36 ET
Fulcrum Therapeutics published news for 2023 q1
SEC form 6
2023-06-23 17:31 ET
Fulcrum Therapeutics published news for 2023 q1
SEC form 6
2023-06-09 16:05 ET
Fulcrum Therapeutics published news for 2023 q1
SEC form 10
2023-05-15 07:08 ET
Fulcrum Therapeutics reported for 2023 q1
SEC form 6
2023-05-15 07:06 ET
Fulcrum Therapeutics reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Fulcrum Therapeutics reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Fulcrum Therapeutics reported for 2023 q1
SEC form 6
2023-04-28 16:02 ET
Fulcrum Therapeutics published news for 2023 q1
SEC form 6
2023-04-18 16:05 ET
Fulcrum Therapeutics published news for 2023 q1
SEC form 6
2023-04-05 08:13 ET
Fulcrum Therapeutics published news for 2023 q1
SEC form 10
2023-03-09 07:21 ET
Fulcrum Therapeutics reported for 2022 q4
SEC form 6
2023-03-09 07:14 ET
Fulcrum Therapeutics reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Fulcrum Therapeutics reported for 2022 q4
SEC form 8
2023-03-09 00:00 ET
Fulcrum Therapeutics reported for 2022 q4
SEC form 6
2023-01-18 17:12 ET
Fulcrum Therapeutics published news for 2022 q4
SEC form 6
2023-01-17 16:53 ET
Fulcrum Therapeutics published news for 2022 q4
SEC form 8
2023-01-17 00:00 ET
Fulcrum Therapeutics published news for 2022 q4
SEC form 6
2023-01-04 07:12 ET
Fulcrum Therapeutics published news for 2022 q4
SEC form 8
2023-01-04 00:00 ET
Fulcrum Therapeutics published news for 2022 q4
SEC form 6
2022-11-09 16:10 ET
Fulcrum Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 07:43 ET
Fulcrum Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 07:36 ET
Fulcrum Therapeutics reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Fulcrum Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Fulcrum Therapeutics reported for 2022 q3
SEC form 6
2022-10-19 16:06 ET
Fulcrum Therapeutics published news for 2022 q3
SEC form 6
2022-08-23 16:58 ET
Fulcrum Therapeutics published news for 2022 q2
SEC form 6
2022-08-16 17:59 ET
Fulcrum Therapeutics published news for 2022 q2
SEC form 6
2022-08-11 16:10 ET
Fulcrum Therapeutics published news for 2022 q2
SEC form 10
2022-08-11 07:31 ET
Fulcrum Therapeutics reported for 2022 q2
SEC form 6
2022-08-11 07:05 ET
Fulcrum Therapeutics published news for 2022 q2
SEC form 6
2022-08-11 07:02 ET
Fulcrum Therapeutics published news for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Fulcrum Therapeutics reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Fulcrum Therapeutics reported for 2022 q2
SEC form 6
2022-07-19 16:15 ET
Fulcrum Therapeutics published news for 2022 q2
SEC form 6
2022-07-11 17:09 ET
Fulcrum Therapeutics published news for 2022 q2
SEC form 6
2022-06-29 17:00 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-29 17:00 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-29 17:00 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-29 17:00 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-29 17:00 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-29 17:00 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-10 16:15 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-09 16:06 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-06 19:00 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-06-06 16:30 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-05-09 21:56 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 10
2022-05-09 07:11 ET
Fulcrum Therapeutics reported for 2022 q1
SEC form 6
2022-05-09 07:04 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Fulcrum Therapeutics reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Fulcrum Therapeutics reported for 2022 q1
SEC form 6
2022-04-28 16:03 ET
Fulcrum Therapeutics published news for 2022 q1
SEC form 6
2022-03-10 16:32 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 10
2022-03-03 07:10 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 6
2022-03-03 07:03 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 10
2022-03-03 00:00 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 8
2022-03-03 00:00 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 16:16 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 07:07 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 6
2022-01-04 16:39 ET
Fulcrum Therapeutics published news for 2021 q4
SEC form 6
2021-12-09 16:15 ET
Fulcrum Therapeutics published news for 2021 q3
SEC form 6
2021-12-06 07:17 ET
Fulcrum Therapeutics published news for 2021 q3
SEC form 6
2021-11-17 08:13 ET
Fulcrum Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 07:16 ET
Fulcrum Therapeutics published news for 2021 q3
SEC form 6
2021-11-04 07:06 ET
Fulcrum Therapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Fulcrum Therapeutics published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Fulcrum Therapeutics published news for 2021 q3
SEC form 6
2021-08-12 16:41 ET
Fulcrum Therapeutics published news for 2021 q2
SEC form 10
2021-08-10 07:08 ET
Fulcrum Therapeutics published news for 2021 q2
SEC form 6
2021-08-10 07:01 ET
Fulcrum Therapeutics published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Fulcrum Therapeutics published news for 2021 q2
SEC form 6
2021-06-24 16:16 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 17:11 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 17:11 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 17:10 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 17:10 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 17:10 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-06-11 16:30 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-05-12 16:15 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 07:08 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 07:05 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 09:00 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-04-02 16:30 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-04-02 16:15 ET
Fulcrum Therapeutics published news for 2021 q1
SEC form 6
2021-03-24 16:30 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 10
2021-03-04 07:11 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 6
2021-03-04 07:05 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 16:30 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 6
2021-02-18 16:30 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 6
2021-02-10 16:15 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 6
2021-01-20 16:05 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 6
2021-01-19 16:05 ET
Fulcrum Therapeutics published news for 2020 q4
SEC form 10
2020-11-10 07:20 ET
Fulcrum Therapeutics published news for 2020 q3
SEC form 6
2020-11-10 07:05 ET
Fulcrum Therapeutics published news for 2020 q3